Loading viewer...
investor_presentation
Format: PDF investor_presentation
Kinnate Biopharma is a clinical-stage precision oncology company developing targeted therapies for cancer. The company's pipeline includes exarafenib (KIN-2787) for BRAF/NRAS-mutant melanoma and KIN-3248 for FGFR-driven cancers, with a proprietary Discovery Engine designed for rapid drug development.
investor_presentation
41 Pages
investor_presentation
24 Pages
J.B. Hunt Transport Services
John Bean Technologies Investor Presentation — July 2022
investor_presentationinvestor_presentation
24 Pages
John Bean Technologies Corporation